Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03356470 · ClinicalTrials.gov registry record
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 5
- Enrollment target
NCT03356470 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 5 participants.
The verdict
NCT03356470 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This study uses molecular imaging and novel immune monitoring to identify a biomarker of response for melanoma patients receiving immunotherapy with anti-PD-1 immunotherapy. Prior to treatment, FDG and FLT PET/CT will be obtained, together with blood and tumor biopsies from each patient. A follow-up FDG and FLT PET/CT will be obtained, together with blood and tumor biopsies, 10-12 weeks after starting treatment with anti-PD-1 antibody. Additional tumor biopsies and blood samples for immune monitoring will be obtained 4-6 weeks after starting treatment with anti-PD-1 antibody as well as 16-18 weeks after starting anti-PD-1 treatment for patients still receiving anti-PD-1 antibody at that time.
Interventions
- OTHER F-FDG PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2022-06-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03356470
The ClinicalTrials.gov registry entry for NCT03356470 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which F-FDG PET/CT is the first listed.
NCT03356470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03356470 about?
NCT03356470 is a clinical study titled "Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma". This study uses molecular imaging and novel immune monitoring to identify a biomarker of response for melanoma patients receiving immunotherapy with anti-PD-1 immunotherapy. Prior to treatment, FDG and FLT PET/CT will be obtained, together with blood and tumor biopsies from each patient. A follow-up...
What is the current status of trial NCT03356470?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2017-11-02. Estimated completion is 2022-06-17.
What interventions are being tested in trial NCT03356470?
The interventions under investigation include: F-FDG PET/CT (OTHER).
Who is sponsoring clinical trial NCT03356470?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.